Novartis will appeal to U.S. Court of Appeals to uphold validity of Entresto® combination patent; maintains 2023 guidance and mid-term outlook
July 07, 2023 15:31 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR U.S. District Court for the District of Delaware ruled the Entresto (sacubitril / valsartan) ‘combination patent’ to be invalid Novartis will appeal...
Sandoz to launch Hyrimoz® (adalimumab-adaz) high-concentration formulation, marking Sandoz entrance into US immunology space
July 01, 2023 00:15 ET
|
Novartis Pharma AG
Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) biosimilar offers US patients reduced injection volume in citrate-free formulationAs one of the only adalimumab HCF biosimilars approved...
Novartis signs agreement to divest ‘front of eye’ ophthalmology assets in line with focused strategy
June 30, 2023 08:00 ET
|
Novartis Pharma AG
Divested assets to include Xiidra®, on-market treatment for dry eye disease and SAF312 (libvatrep), potential therapy for chronic ocular surface painDeal consistent with Novartis focused strategy of...
Sandoz introduces Act4Biosimilars Action Plan to accelerate patient access to biosimilar medicines
June 15, 2023 01:15 ET
|
Novartis Pharma AG
Despite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while reference medicines still represent 86% of biologic...
Novartis bolsters innovative medicines strategy and renal pipeline with agreement to acquire Chinook Therapeutics for USD 3.2bn upfront (USD 40 / share)
June 12, 2023 01:00 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare,...
Sandoz presents compelling investment proposition as standalone company at Capital Markets Day
June 08, 2023 01:15 ET
|
Novartis Pharma AG
Sandoz well positioned to deliver continued mid-single digit sales growth; core EBITDA margin of 24-26% and Free Cash Flow to more than double over mid term European champion committed to further...
Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups
June 02, 2023 08:00 ET
|
Novartis Pharma AG
Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with HR+/HER2- early breast cancer, regardless of...
Sandoz plans move to new central Basel headquarters by mid-2024, following proposed spin-off as standalone company
June 01, 2023 01:15 ET
|
Novartis Pharma AG
Sandoz AG to remain based in Basel, Switzerland following proposed spin-off from Novartis Announcement of planned city-center HQ marks important milestone as Sandoz prepares to become independent...
Sandoz Marketing Authorization Applications for proposed biosimilar denosumab accepted by EMA
May 25, 2023 01:15 ET
|
Novartis Pharma AG
Submissions supported by comprehensive analytical and clinical data package including a Phase I PK/PD similarity study and the integrated Phase I/III ROSALIA clinical trialDenosumab is indicated for...
New Sandoz Board of Directors appointed
May 15, 2023 01:15 ET
|
Novartis Pharma AG
Novartis Board of Directors approves the recommendation of Sandoz Chairman-designate for the future Sandoz Board of Directors, to start preparatory work in June, followed by formal constitution in H2...